Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 371087, 14 pages
http://dx.doi.org/10.1155/2014/371087
Clinical Study

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

1Department of Bio-Therapy, College of Life Sciences, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China
2Department of Geriatric Hematology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China
3Department of Immunology, Institute of Basic Medicine, Medical College of PLA, Chinese PLA General Hospital, Beijing 100853, China

Received 26 December 2013; Revised 21 March 2014; Accepted 10 April 2014; Published 21 May 2014

Academic Editor: Shigeo Koido

Copyright © 2014 Hui Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. D. B. Longley and P. G. Johnston, “Molecular mechanisms of drug resistance,” Journal of Pathology, vol. 205, no. 2, pp. 275–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard, “An operational definition of epigenetics,” Genes and Development, vol. 23, no. 7, pp. 781–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Sharma, T. K. Kelly, and P. A. Jones, “Epigenetics in cancer,” Carcinogenesis, vol. 31, no. 1, pp. 27–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Taby and J.-P. Issa, “Cancer epigenetics,” CA Cancer Journal for Clinicians, vol. 60, no. 6, pp. 376–392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Gomes, M. Reis-Silva, and A. Alarcao, “Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung,” Revista Portuguesa de Pneumologia, vol. 20, no. 1, pp. 20–30, 2014. View at Google Scholar
  7. J. Peedicayil, “The role of DNA methylation in the pathogenesis and treatment of cancer,” Current Clinical Pharmacology, vol. 7, no. 4, pp. 333–340, 2012. View at Google Scholar
  8. M. Sang, X. Wu, X. Fan et al., “Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer,” Biomarkers, vol. 19, no. 1, pp. 34–42, 2014. View at Google Scholar
  9. R. Gurion, L. Vidal, A. Gafter-Gvili, Y. B. Yeshurun, P. Raanani, and O. Shpilberg, “5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome—a systematic review and meta-analysis,” Haematologica, vol. 95, no. 2, pp. 303–310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. F. Cashen, G. J. Schiller, M. R. O'Donnell, and J. F. DiPersio, “Multicenter, phase II study of decitabine for the first-line treatment of older patients with Acute Myeloid Leukemia,” Journal of Clinical Oncology, vol. 28, no. 4, pp. 556–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gnyszka, Z. Jastrzebski, and S. Flis, “DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer,” Anticancer Research, vol. 33, no. 8, pp. 2989–2996, 2013. View at Google Scholar
  12. T. K. Kelly, D. D. de Carvalho, and P. A. Jones, “Epigenetic modifications as therapeutic targets,” Nature Biotechnology, vol. 28, no. 10, pp. 1069–1078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Blum, R. B. Klisovic, B. Hackanson et al., “Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3884–3891, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L.-X. Wang, Z.-Y. Mei, J.-H. Zhou et al., “Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T Lymphocyte Responses,” PLoS ONE, vol. 8, no. 5, Article ID e62924, 2013. View at Google Scholar
  15. P. Wijermans, M. Lübbert, G. Verhoef et al., “Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients,” Journal of Clinical Oncology, vol. 18, no. 5, pp. 956–962, 2000. View at Google Scholar · View at Scopus
  16. H. Kantarjian, Y. Oki, G. Garcia-Manero et al., “Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia,” Blood, vol. 109, no. 1, pp. 52–57, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. B. F. Chu, M. J. Karpenko, Z. Liu et al., “Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 1, pp. 115–121, 2013. View at Google Scholar
  18. L. M. Kopp, A. Ray, C. J. Denman et al., “Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions,” Molecular Immunology, vol. 54, no. 3-4, pp. 296–301, 2013. View at Google Scholar
  19. Y. Zhang, J. Wang, Y. Wang et al., “Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy,” Clinical and Developmental Immunology, vol. 2013, Article ID 195691, 12 pages, 2013. View at Publisher · View at Google Scholar
  20. M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, “A gene hypermethylation profile of human cancer,” Cancer Research, vol. 61, no. 8, pp. 3225–3229, 2001. View at Google Scholar · View at Scopus
  21. J. Lotem and L. Sachs, “Epigenetics and the plasticity of differentiation in normal and cancer stem cells,” Oncogene, vol. 25, no. 59, pp. 7663–7672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Hirata, Y. Hinoda, K. Nakajima et al., “Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma,” International Journal of Cancer, vol. 128, no. 8, pp. 1793–1803, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. G. Chun, W. Zhou, and N. S. Yee, “Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer,” Cancer Biology & Therapy, vol. 8, no. 14, pp. 1328–1339, 2009. View at Google Scholar · View at Scopus
  24. A. Lundqvist, S. I. Abrams, D. S. Schrump et al., “Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity,” Cancer Research, vol. 66, no. 14, pp. 7317–7325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Fonsatti, H. J. M. Nicolay, L. Sigalotti et al., “Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications,” Clinical Cancer Research, vol. 13, no. 11, pp. 3333–3338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. W. E. Samlowski, S. A. Leachman, M. Wade et al., “Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation,” Journal of Clinical Oncology, vol. 23, no. 17, pp. 3897–3905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. E. Vigil, T. Martin-Santos, and G. Garcia-Manero, “Safety and efficacy of azacitidine in myelodysplastic syndromes,” Drug Design, Development and Therapy, vol. 4, pp. 221–229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Stathis, S. J. Hotte, E. X. Chen et al., “Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas,” Clinical Cancer Research, vol. 17, no. 6, pp. 1582–1590, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. E. George, J. M. Lahti, P. C. Adamson et al., “Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a children's oncology group study,” Pediatric Blood and Cancer, vol. 55, no. 4, pp. 629–638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Appleton, H. J. Mackay, I. Judson et al., “Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4603–4609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. B. Yoo and P. A. Jones, “Epigenetic therapy of cancer: past, present and future,” Nature Reviews Drug Discovery, vol. 5, no. 1, pp. 37–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J.-P. J. Issa, “DNA methylation as a therapeutic target in cancer,” Clinical Cancer Research, vol. 13, no. 6, pp. 1634–1637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Jabbour, J.-P. Issa, G. Garcia-Manero, and H. Kantarjian, “Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies,” Cancer, vol. 112, no. 11, pp. 2341–2351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Karahoca and R. L. Momparler, “Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy,” Clin Epigenetics, vol. 5, no. 1, article 3, 2013. View at Google Scholar
  35. J. Bauman, C. Verschraegen, S. Belinsky et al., “A phase i study of 5-azacytidine and erlotinib in advanced solid tumor malignancies,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 2, pp. 547–554, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. D. S. Schrump, M. R. Fischette, D. M. Nguyen et al., “Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura,” Clinical Cancer Research, vol. 12, no. 19, pp. 5777–5785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. D. K. Krishnadas, L. Bao, F. Bai et al., “Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1,” Tumor Biology, 2014. View at Publisher · View at Google Scholar
  38. V. Santini, H. M. Kantarjian, and J.-P. Issa, “Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications,” Annals of Internal Medicine, vol. 134, no. 7, pp. 573–586, 2001. View at Google Scholar · View at Scopus